All news

Argus upgrades ELV to Buy with $510 target

Alpha Vantage · TradingView · · AI-summarised by FinFlash

Argus Research has upgraded Elevance Health (ELV) to Buy from Hold, setting a price target of $510. This target suggests a 17.5% upside from the stock's closing price of $433.93 on November 17. Recent analyst actions on Elevance Health have seen price targets ranging from $449 to $523 over the past month.

Read original source

ELV company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.